

David MORTON

***Consultant
Aerosol Scientist***



Professor David Morton has developed formulation solutions used in numerous marketed pharmaceutical aerosol inhalers.

David originally developed his aerosol science expertise in the UK at AEA Technology, leading national studies into hazardous radioactive aerosol containment issues. He translated this knowledge as a founding member of the drug delivery start-up company Vectura Group plc, where he led the development Vectura's aerosol inhalation technology platforms and products. This includes devising the PowderHale® formulation technologies, now used extensively, notably in marketed products including Novartis BreezeHaler®, Chiesi NEXThaler® and GSK Ellipta® medicines.

David developed an international leadership position, as co-chair of the "Drug Delivery to the Lungs" conference series for over 10 years. In 2007, David joined Monash University, extending research interests in particle engineering, and commercial drug delivery formulation technologies. David is co-inventor of the Monash Oxytocin dry powder inhaler technology recognized with the 2013 Australian Innovation of the Year Award.

He led creation of The CoI2, a uniquely effective partnership with GSK in advanced manufacturing and pharma training, with awards including the B-HERT Outstanding Collaboration in Australia and Best Australian R&D Collaboration. He worked extensively with inhaled products manufactured by GSK, including Relenza. In 2016 he guided the evolution of CoI2 into the Medicines Manufacturing Innovation Centre.

He is currently Professor at The School of Engineering at Deakin University of Melbourne. David has authored over 35 patent applications, and despite his industrial career has over 100 peer-reviewed academic publications, and around 4,000 citations.